ArriVent BioPharma, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVBP research report →
Companywww.arrivent.com
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors.
- CEO
- Zhengbin Yao
- IPO
- 2024
- Employees
- 52
- HQ
- Newtown Square, US
Price Chart
Valuation
- Market Cap
- $1.27B
- P/E
- -8.45
- P/S
- 0.00
- P/B
- 3.79
- EV/EBITDA
- -7.97
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -48.98%
- ROIC
- -48.36%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-166,308,000 · -106.62%
- EPS
- $-4.32 · -68.75%
- Op Income
- $-177,534,000
- FCF YoY
- -128.72%
Performance & Tape
- 52W High
- $32.14
- 52W Low
- $16.10
- 50D MA
- $26.78
- 200D MA
- $22.27
- Beta
- 1.52
- Avg Volume
- 492.56K
Get TickerSpark's AI analysis on AVBP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 2, 26 | LaChapelle Robin | other | 130,000 |
| Feb 2, 26 | Lutzker Stuart | other | 150,000 |
| Feb 2, 26 | Kung Winston | other | 140,000 |
| Feb 2, 26 | Yao Zhengbin | other | 550,000 |
| Feb 2, 26 | Kastenmayer James Paul | other | 130,000 |
| Dec 10, 25 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | sell | 555,555 |
| Jul 11, 25 | LaChapelle Robin | other | 6,503 |
| Jul 11, 25 | LaChapelle Robin | other | 2,600 |
| Jul 11, 25 | LaChapelle Robin | other | 2,050 |
| Jul 11, 25 | LaChapelle Robin | other | 2,600 |
Our AVBP Coverage
We haven't published any research on AVBP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVBP Report →